Bausch Health Cos Inc. (NYSE:BHC – Get Free Report) Director Frank Lee sold 24,456 shares of the stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total value of $132,796.08. Following the completion of the transaction, the director owned 49,339 shares in the company, valued at approximately $267,910.77. This represents a 33.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Bausch Health Cos Stock Up 3.5%
Shares of BHC traded up $0.19 during trading hours on Wednesday, reaching $5.51. The stock had a trading volume of 1,876,907 shares, compared to its average volume of 1,978,303. Bausch Health Cos Inc. has a 12 month low of $4.41 and a 12 month high of $8.69. The firm has a 50-day simple moving average of $5.42 and a 200 day simple moving average of $6.14. The company has a current ratio of 1.32, a quick ratio of 0.97 and a debt-to-equity ratio of 54.68. The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of -1.70 and a beta of 0.42.
Bausch Health Cos (NYSE:BHC – Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $0.78 earnings per share for the quarter, missing the consensus estimate of $0.81 by ($0.03). Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%. The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.37 billion. Equities research analysts predict that Bausch Health Cos Inc. will post 4.08 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Bausch Health Cos
Key Bausch Health Cos News
Here are the key news stories impacting Bausch Health Cos this week:
- Positive Sentiment: Shareholders approved all 10 director nominees at Bausch Health’s 2026 Annual Meeting, including the election of new director Dr. Eiry W. Roberts, which signals continuity in governance and adds a director with pharma and clinical development experience. Bausch Health Announces 2026 Annual Meeting of Shareholder Results
- Positive Sentiment: Zacks Research raised its FY2026 EPS estimate slightly for Bausch Health, reflecting a modest improvement in expected full-year profitability.
- Neutral Sentiment: The company presented at the RBC Capital Markets Global Healthcare Conference and Barclays Leveraged Finance Conference; these events can give management a chance to reinforce its strategy, but the transcripts did not include a clear new catalyst in the supplied headlines. Bausch Health Companies Inc. (BHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript Bausch Health Companies Inc. (BHC) Presents at Barclays 30th Annual Leveraged Finance Conference 2026 Transcript
- Negative Sentiment: Zacks Research cut several out-year earnings estimates, including FY2027, FY2028, and specific 2027–2028 quarterly forecasts, which may raise concerns about longer-term growth and margin expectations.
Analyst Ratings Changes
Several equities analysts have weighed in on the company. Royal Bank Of Canada dropped their price objective on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Monday, April 27th. Barclays lowered their target price on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 25th. Raymond James Financial reiterated a “market perform” rating on shares of Bausch Health Cos in a research note on Monday, January 26th. Weiss Ratings cut Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 4th. Finally, Wall Street Zen cut Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 15th. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $8.00.
View Our Latest Analysis on Bausch Health Cos
Bausch Health Cos Company Profile
Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.
The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.
Featured Stories
- Five stocks we like better than Bausch Health Cos
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for Bausch Health Cos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Cos and related companies with MarketBeat.com's FREE daily email newsletter.
